Clinical Trial Detail

NCT ID NCT03559049
Title Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors University of Michigan Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Pembrolizumab + Pemetrexed + Rucaparib

Age Groups: senior adult

Additional content available in CKB BOOST